SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (14428)12/2/2004 12:56:15 PM
From: Ian@SI  Read Replies (1) of 52153
 
Doesn't Macugen have to be approved first? <vbg>

Even with PFE as a partner, I still don't see this as a slam dunk. After Vioxx, the leaderless FDA is likely to be a bit more gunshy especially when there are safety concerns and questionable efficacy relative to existing approved treatments.

IMO,
Ian

ENZN is about at breakeven, and will likely move into profitability with royalties from Macugen.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News